Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Non Small Cell Lung Cancer Clinical Trial

— ANDROMEDA  

Official title:

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - An Open Label Randomized Phase III Trial Comparing Up-front Radiation in Oligometastatic Non-small Cell Lung Cancer (NSCLC) and Systemic Treatment With Systemic Treatment Alone

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06141070
• Other study ID #: The ANDROMEDA trial
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 1, 2023
• Est. completion date: December 1, 2027

Study information

• Verified date: November 2023
• Source: Vastra Gotaland Region
• Contact: Andreas Hallqvist
• Phone: +46313427954
• Email: andreas.hallqvist[@]vgregion.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC. Stratification factors: performance status, gender and systemic strategy. The systemic treatment consists of chemotherapy/chemoimmunotherapy or immunotherapy and is given according to local practice. During the first 3 months of systemic treatment, aiming to start around the 2nd cycle is radiotherapy delivered to all known lesions. Preferably with SBRT /SRT/SRS but conventional radiotherapy may also be used. After the first three cycles of systemic treatment, the patients are assessed, and after four cycles, they are continuing maintenance therapy if indicated. The patients are followed with radiology every three months.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 240
• Est. completion date: December 1, 2027
• Est. primary completion date: December 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening procedures
• Histological or cytological diagnosis of NSCLC
• Stage IV disease with =5 metastases (not including primary tumour or mediastinal nodes, N1-N3)
• Patient deemed fit for first line chemoimmunotherapy, immunotherapy or chemotherapy
• Extra-thoracic metastases accessible for stereotactic body radiotherapy (SBRT)
• Thoracic tumour(s) accessible for SBRT or conventional radiotherapy
• Received no prior systemic treatment or radiation therapy for NSCLC (previous adjuvant systemic therapy is allowed)
• Age > 18 years at time of study entry, no upper age limit
• WHO performance status 0-2
• Adequate normal organ and marrow function Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects.
• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria:

• • Solitary brain lesion or contralateral lung lesion as the only distant metastasis
• Participation in another clinical study with an investigational product during the last 4 weeks
• Patients with EGFR+, ALK+, ROS1+ disease or any other genetic alteration that would result in a TKI based first line treatment (i.e. first line treatment not being chemoimmuno- or immunotherapy)
• Malignant pleural fluid, or ascites (malignant cells or clinical judgement) or excessive fluid hampering radiation according to protocol
• Leptomeningeal disease
• Pulmonary fibrosis making protocol stipulated treatment hazardous (low grade radiologic findings are allowed as assessed by the investigator)
• Not deemed fit for standard first line systemic therapy
• Second primary residual malignancy. Other malignancy diagnosed and treated > 2 years ago without relapse and deemed to have a low likelihood of relapse is allowed. (Carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin < 2 years are allowed, as is other low-grade malignancy with low likelihood of becoming metastatic or impact on survival e.g. low-grade prostate cancer not in need of treatment)
• Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of systemic therapy
• Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Other:
• Standard systemic therapy + radiotherapy
Combined systemic therapy + radiation

Drug:
• Standard systemic therapy
Chemoimmunotherapy or immunotherapy

Locations

Country	Name	City	State
Sweden	Dept of Oncology	Gothenburg
Sweden	Dept of pulmonary medicine	Linköping
Sweden	Dept of pulmonary medicine	Lund
Sweden	Dept of Oncology	Stockholm
Sweden	Dept. of Oncology	Umeå
Sweden	Dept. of Oncology	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival (OS)	Time to death	From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months
Secondary	Progression-free survival (PFS)	Time to progressive disease or death	From date of randomization until the date of first documented systemic progression or date of death from any cause, whichever came first, assessed up to 60 months
Secondary	Local control (LC)	Percentage complete, partial remission or stable disease	At 12 months after randomization